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Abstract
Purpose To investigate risk factors for severe bleeding during warfarin treatment, including the influence of sex, age, comor-
bidity and co-medication on bleeding risk.
Methods Patients initiating warfarin treatment between 2007 and 2011 were identified in the nationwide Swedish
Prescribed Drug Register, and diagnoses of severe bleeding were retrieved from the National Patient Register.
Hazard ratios (HR) with 95% confidence intervals (CI) for severe bleeding were estimated using multiple Cox
regression adjusting for indications and including covariates age, sex, comorbidities and co-medications. Interactions
between sex and other covariates were investigated.
Results The study cohort included 232,624 patients ≥ 18 years (101,011 women and 131,613 men). The incidence rate
of severe bleeding was 37 per 1000 person-years, lower among women than men with an adjusted HR (95% CI) of
0.84 (0.80–0.88). Incidence of bleeding increased with age, HR 2.88 (2.37–3.50) comparing age ≥ 80 to < 40 years,
and comorbidities associated with the highest risk of severe bleeding were prior bleeding, HR 1.85 (1.74–1.97); renal
failure, HR 1.82 (1.66–2.00); and alcohol dependency diagnosis, HR 1.79 (1.57–2.05). Other comorbidities signifi-
cantly associated with bleeding events were hypertension, diabetes, peripheral vascular disease, congestive heart
failure, liver failure, stroke/TIA, COPD and cancer.
Conclusion Most of the well-established risk factors were found to be significantly associated with bleeding events in our study.
We additionally found that women had a lower incidence of bleeding. Potential biases are selection effects, residual confounding
and unmeasured frailty.
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Introduction
There are several known risk factors for bleeding during
treatment with oral anticoagulants, such as age, chronic
comorbidities, prior bleeding and certain co-medications
which are included in the HAS-BLED score [1]. Sex is
not included in this risk score, and conflicting results have
been found in different populations with several studies
showing no difference in bleeding risk between the sexes
[2–7], while other studies found a higher risk of bleeding
in men [8–11]. To our knowledge, there is a lack of large
population-based register studies on sex differences in se-
vere bleeding risks in warfarin-treated patients. Therefore,
we performed a study using national health registers with
the aim to investigate risk factors for severe bleeding after
initiation of warfarin including the influence of sex on the
incidence of bleeding events.
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Methods
Data sources
As data sources in this study, we used Swedish national
health registers covering the entire population. Data were
linked using the personal identity number (PIN) that
uniquely identifies all citizens in Sweden. For informa-
tion on dispensed prescription on warfarin and co-medi-
cation, we used the Swedish Prescribed Drug Register
(PDR), held by the National Board of Health and
Welfare, with data on all dispensed prescriptions in
Sweden since July 2005 [12], including Anatomical
Therapeutic Chemical classification (ATC) codes [13].
The coverage of the PDR is high with > 99.7% of all
prescriptions being recorded with PINs [14]. Diagnoses
corresponding to the indications for warfarin treatment,
comorbidity and bleeding diagnoses were identified
through the Swedish National Patient Register (NPR)
[15–18]. The NPR holds information on primary and
up to 30 secondary diagnoses from all hospitalizations,
nationwide since 1987 and outpatient encounters since
2001. Diagnoses are recorded by the International
Classification of Diseases (ICD) system, and the version
used in this study is the 10th version (ICD-10), used
since 1997. Additionally, the register holds information
on surgical procedures performed at hospitals using the
Nordic Classification of Surgical Procedures [19].
Information on cancer, including the date of diagnosis,
was retrieved from the Swedish Cancer Register [20].
The Cause of Death Register [21] and the Register of
the Total Population [22] hold information on individ-
ual’s sex, dates of birth, death and migration. Register
data were de-identified for research use.
Study population and follow-up
Women and men over 18 years of age with a dispensed
warfarin prescription (ATC code B01AA03) in PDR dur-
ing the study period January 1, 2007, until December 31,
2011, were included in the study cohort. The inclusion
period ended before the introduction of non-vitamin K
oral anticoagulants (NOACs). The index date was the
first date of a warfarin dispensing during this period.
We only included new users, i.e. patients with no vitamin
K antagonist (VKA) use 1 year prior to index date. We
excluded subjects not resident in Sweden the year before
and included the index date (Fig. 1). All patients in the
cohort were followed for the occurrence of bleeding
events until a maximum of 12 months after the index
date, emigration or death, whichever occurred first (in-
tention-to-treat-like approach).
Indications
The PDR does not hold information on the indication for drug
treatment, and therefore, we as proxies included covariates
corresponding to the likely indications of warfarin identified
in the NPR through the main and secondary discharge diag-
nosis, as well as the outpatient visit diagnosis (suppl. Table 1).
The indications for warfarin included in the analyses were
venous thrombosis (VT), pulmonary embolism (PE), venous
thromboembolism (VTE) prophylaxis, peripheral systemic
embolism, vascular prosthesis, valvular disease, valvular and
non-valvular atrial fibrillation (VAF and NVAF), cardiover-
sion, cardiomyopathy, valvular prosthesis and mitral stenosis.
For VAF and NVAF, we used diagnoses occurring up to
10 years before the index date, and for the other indications,
we used a time window of 3 months before the index date. In
the analysis, a patient could be classified as having several
possible indications.
Outcomes
The primary outcome was the first severe bleeding event lead-
ing to hospitalization, identified as a main or secondary diag-
nosis in the NPR. We used the approach for identification of
severe bleeding in health registers validated by Friberg et al.
[23]. As secondary outcomes, we investigated severe bleeding
categorized by anatomical site [23] (Suppl. Table 2).
Comorbidity and co-medication
In the analyses, we included covariates representing comor-
bidities and co-medications. For comorbidities, similar defini-
tions and International Classification of Diseases, 10th revi-
sion (ICD-10) codes as in two previous studies [14, 24] were
used, supplemented with definitions and diagnoses used in the
Charlson comorbidity index (CCI) [25, 26] (Suppl. Table 1).
Hospital admissions and outpatient contacts for comorbidities
were identified up to 10 years before the index date, as were
recorded in the cancer registry. Because of the lack of infor-
mation on international normalized ratio (INR), a modified
HAS-BLED score [1, 27] without INR was used for classify-
ing the risk of severe bleeding (Suppl. Table 3). As co-medi-
cation, the covariates we included were low-dose aspirin, oth-
er antiplatelet agents, NSAIDs, proton pump inhibitors (PPIs),
systemic corticosteroids, antidepressants, selective serotonin
reuptake inhibitors (SSRIs), antidiabetics and alcohol depen-
dency drugs dispensed within 1 year before index date (Suppl.
Table 4). Female hormone therapy was not included due to the
different indications and the very different prevalence of use
in women and men. However, we performed a restricted anal-
ysis excluding patients treated with female hormones. Drugs
assessed as having clinically relevant drug interactions with
warfarin, i.e. azole antibiotics, macrolides, quinolones, lipid-
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lowering agents, amiodarone and fluorouracil [28], were also
included in the analyses (Suppl. Table 4). These consist of
drugs where it is either recommended to avoid concomitant
treatment with warfarin (D-interactions) or recommended to
monitor INR for warfarin dose adjustment (C-interactions)
[29].
Ethical approval
The study was approved by the Regional Ethical Review
Board at Karolinska Institutet (Stockholm, Sweden; Dnr
2013/1850-31/1 and 2014/2215-32).
Statistics
Descriptive statistics are presented as numbers and propor-
tions. Using multiple Cox regression, we estimated hazard
ratios (HR) for severe bleeding in models including as covar-
iates sex, age, comorbidities and co-medication. The HRs
were presented with a 95% confidence interval (CI). We final-
ly investigated the effect modification for each covariate by
including an interaction term between the covariate and sex in
the model. In additional regression models, we adjusted for
age as a continuous variable instead of categorical and includ-
ed co-medications that could lead to drug interactions with
warfarin. All analyses were carried out using SAS® software,
Version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
We included 232,624 patients (101,011 women and 131,613
men) in the cohort. Baseline characteristics of the study pop-
ulation are presented in Table 1. The mean (SD) age was
72.2 years for women and 68.5 years for men, with an excess
of persons in the age group ≥ 80 years among females.
The most common indications for warfarin treatment were
atrial fibrillation, venous thromboembolism (VT and PE),
followed by valvular diseases. The indications for warfarin
treatment differed between women and men, with VT, PE
and NVAF being more common in women compared to
men. On the other hand, less women than men had valvular
disease. Themost common comorbidities were cardiovascular
diseases, i.e. hypertension, ischemic heart disease, and con-
gestive heart failure, followed by ischemic stroke or TIA. The
frequency of comorbidities also differed between the sexes
(Table 1) with, e.g. more women with hypertension but more
men with diabetes mellitus, myocardial infarction and ische-
mic heart disease.Womenmore often had “high”HAS-BLED
risk scores. There were also sex differences in co-medication,
with more women treated with NSAIDs, PPIs, antidepres-
sants, SSRIs and systemic corticosteroids, compared to men.
More men than women were treated with low-dose aspirin,
other antiplatelet agents, alcohol dependency drugs and
antidiabetics.
The crude incidence rate of severe bleeding was 37 per
1000 person-years, in women 35 and in men 38 per 1000
Fig. 1 Study flow chart
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Table 1 Warfarin study cohort characteristics
Women Men
N % N %
Total 101,011 100.0 131,613 100.0
Age, y mean (SD) 72.2 (13.9) 68.5 (12.8)
Age group, y
< 40 4045 4.0 4012 3.0
40–49 3789 3.8 7125 5.4
50–59 6435 6.4 15,695 11.9
60–69 19,165 19.0 37,172 28.2
70–79 33,169 32.8 41,571 31.6
≥ 80 34,408 34.1 26,038 19.8
Indicationsa
Venous thrombosis 5918 5.9 5751 4.4
Pulmonary embolism 12,734 12.6 12,838 9.8
VTE prophylaxis 1899 1.9 1333 1.0
Peripheral systemic embolism 1144 1.1 938 0.7
Vascular prosthesis 390 0.4 1075 0.8
Valvular disease 5544 5.5 8871 6.7
Valvular atrial fibrillation 4414 4.4 5932 4.5
Non-valvular atrial fibrillation 39,038 38.6 47,470 36.1
Cardioversion 734 0.7 1142 0.9
Cardiomyopathy 790 0.8 2133 1.6
Valve prosthesis 2676 2.6 4816 3.7
Mitral stenosis 245 0.2 95 0.1
Comorbidities/risk factorsa
Hypertensionc 42,475 42.0 46,092 35.0
Diabetes mellitus 10,964 10.9 16,237 12.3
Myocardial infarction 10,080 10.0 19,448 14.8
Ischemic heart disease 17,618 17.4 30,220 23.0
Peripheral vascular disease 3567 3.5 6420 4.9
Congestive heart failure 14,448 14.3 20,348 15.5
Renal failurec 2042 2.0 3748 2.8
Liver failurec 659 0.7 1132 0.9
Ischemic stroke or TIAc 15,355 15.2 18,038 13.7
COPD/emphysema 5482 5.4 5867 4.5
Cancer (excl. Non-melanoma skin cancer) 8644 8.6 11,784 9.0
Alcohol dependency diagnosisc 745 0.7 3024 2.3
Platelet or coagulation disorder 1053 1.0 1012 0.8
Prior bleedingc 3913 3.9 4941 3.8
Co-medicationb
Low-dose aspirinc 42,664 42.2 59,273 45.0
Other antiplatelet agentsc 6861 6.8 11,235 8.5
NSAIDsc 22,645 22.4 26,197 19.9
PPIs 28,836 28.5 27,979 21.3
Antidepressants 16,301 16.1 11,133 8.5
Systemic corticosteroids 15,499 15.3 14,032 10.7
Female hormone therapy and contraceptives 22,085 21.9 97 0.1
Alcohol dependency drugsc 144 0.1 653 0.5
Antidiabetics 11,151 11.0 17,920 13.6
Interactionsb
D interactions 2935 2.9 2701 2.1
Fluconazole 2031 2.0 879 0.7
Sulfamethoxazole 1012 1.0 1947 1.5
C interactions 42,606 42.2 53,605 40.7
HAS-BLED risk score, mean (SD) 2.0 (1.2) 1.8 (1.2)
HAS-BLED risk score
Low risk (0–1 points) 36,362 36.0 55,836 42.4
Intermediate risk (2 points) 30,318 30.0 37,937 28.8
High risk (≥ 3 points) 34,331 34.0 37,840 28.8
a See supplementary Table 1 for definitions
b See supplementary Table 4 for definitions
c Included in the modified HAS-BLED score
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person-years. In the analyses of overall risk of severe bleed-
ing, we found a significantly lower risk in women compared
tomen with a crude HR (95%CI) of 0.94 (0.90–0.98) that was
further reduced 0.84 (0.80–0.88) after adjustment for age, in-
dications, comorbidities and co-medication (Table 2).
Table 2 shows the association of covariates with severe
bleeding risk. Indications for warfarin associated with a higher
risk of severe bleeding were valvular disease with a HR of
1.53 (1.35–1.74), venous thrombosis 1.32 (1.20–1.44), pe-
ripheral systemic embolism 1.40 (1.17–1.67) and pulmonary
embolism 1.14 (1.07–1.23). Comorbidities associated with
the highest risk of severe bleeding were prior bleeding 1.85
(1.74–1.97), renal failure 1.82 (1.66–2.00) and alcohol depen-
dency diagnosis 1.79 (1.57–2.05). Co-medications associated
with a higher risk of severe bleeding were “other antiplatelet
agents”, NSAIDs, PPIs, antidepressants, SSRIs, systemic cor-
ticosteroids and alcohol dependency drugs with HR (95% CI)
1.49 (1.11–1.99).
Among drugs with a known interaction with warfarin, only
sulfamethoxazole, ciprofloxacin and simvastatin significantly
influenced bleeding risk in an adjusted analysis (data not
shown). Including these covariates in the analysis did not
change our estimates.
In the analysis of site-specific severe bleedings (Suppl
Table 5), women had a lower adjusted risk of CNS bleeding
and urogenital bleeding than men, while there was no differ-
ence in the risk of GI bleeding and other bleedings.
In the analyses of effect modification (Suppl Table 6),
women in the age groups 40–49 and 50–59 had a higher risk
of severe bleeding thanmen. The lower severe bleeding risk in
women was independent of indications, HAS-BLED score
and comorbidities except renal failure, COPD and prior bleed-
ing. For patients with renal failure, the risk in women
exceeded the risk in men. For co-medications, only low-dose
aspirin differed from the general pattern with an even more
pronounced lower risk of severe bleeding in women (Suppl
Table 6).
Adjustments for age as a continuous variable did not
change the overall estimates. Neither did the exclusion of
patients receiving female hormone therapy and contraceptives
lead to important changes in HRs.
Discussion
In our study, we found that the risk of severe bleeding was
significantly associated with the majority of the risk factors
included in the HAS-BLED score: age, hypertension, renal
and liver failure, ischemic stroke or TIA, prior bleeding, alco-
hol dependency and co-medication with antiplatelet agents
and NSAIDs. We additionally found a higher bleeding risk
associated with other factors: diabetes, peripheral vascular
disease, congestive heart failure, COPD and cancer.
Furthermore, we found an overall lower risk of severe bleed-
ing during warfarin treatment in women compared to men,
even more pronounced after adjustment for other factors.
The HAS-BLED risk score has been compared to other risk
scores which include additional or other risk factors, such as
diabetes and cancer [30–32]. Cancer patients with venous
thrombosis are more likely to develop major bleeding during
anticoagulant treatment than those without malignancy [33].
Diabetes and congestive heart failure have not previously been
associated with a higher bleeding risk during treatment with
anticoagulants [34, 35]. A higher bleeding risk during warfa-
rin treatment after 2 years was seen in patients with peripheral
artery disease (PAD) [36]. An association between a higher
risk of GI-bleeding in patients with COPD has also previously
been found [37, 38].
The finding of a lower risk of severe bleeding during war-
farin treatment in women is in line with two other studies. A
study with elderly patients with AF or VT on VKA treatment
with a higher rate of bleeding events in men [10] and a
Swedish cohort study onwarfarin-naïvepatients showingmale
sex as an independent risk factor of severe bleeding [9]. The
lower risk of CNS bleeding in women found in our study was
also in line with another Swedish study on warfarin-treated
AF patients [8]. Furthermore, despite the on average lower
risk and consistency across analyses stratified on most risk
factors, our results showed that in the age groups of 40–49
and 50–59 and in patients with renal failure, women may have
a higher risk of severe bleeding than men.
In a study on older patients with VKAs [39], frequent use of
NSAIDs or selective COX-2-inhibitors was a strong risk factor
for upper gastrointestinal haemorrhage. In our study, however,
co-medication with NSAIDs only slightly increased bleeding
risk (Table 2). This could be due to the physicians selecting
low-risk patient for combination therapy. Concomitant use of
aspirin or other antiplatelet drugs in patients with anticoagulants
is a known risk factor for bleeding complications [40, 41] with
an especially high risk in elderly patients [42, 43]. The risk of
low-dose aspirin disappeared in the adjusted analysis (Table 2),
which may be explained by a similar selection effect or corre-
lation of aspirin use with other strong risk factors.
Our findings of a lower risk of severe bleeding in women
compared to men should be viewed in the light of the risk
benefit balance for stroke prevention in women with AF on
warfarin, where the differences in the epidemiology of stroke
among women and men must be acknowledged. In Sweden,
men are more frequently prescribed antithrombotic treatment
compared to women [44], and the national US registry data
show that women were significantly less likely to use any oral
anticoagulant for AF overall and at all levels of CHA2DS2-
VASc score compared to men [45]. Data from a global register
study on patients with newly diagnosed NVAF show that the
use of anticoagulant therapy for stroke prevention is similar
for women and men (approximately 60%), with underuse of
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Table 2 Hazard ratios (HR) for
severe bleeding: associations with
sex, age groups, indications, co-
morbidities, risk factors for
bleeding and co-medication. Cox
regression, crude and adjusted for
all covariates
Crude Adjusted
HR (95% CI) HR (95% CI)
Women vs. men 0.94 (0.90–0.98) 0.85 (0.81–0.89)
Age group, y
< 40 1 (reference) 1 (reference)
40–49 1.23 (0.97–1.55) 1.13 (0.89–1.42)
50–59 1.66 (1.35–2.04) 1.41 (1.15–1.74)
60–69 2.06 (1.70–2.50) 1.67 (1.38–2.03)
70–79 2.80 (2.32–3.38) 2.19 (1.81–2.66)
≥ 80 3.80 (3.15–4.59) 2.88 (2.37–3.50)
Indicationsa
Venous thrombosis 1.33 (1.22–1.46) 1.32 (1.20–1.44)
Pulmonary embolism 1.12 (1.04–1.19) 1.14 (1.07–1.23)
VTE prophylaxis 1.11 (0.93–1.32) 1.05 (0.88–1.25)
Peripheral systemic embolism 1.81 (1.52–2.16) 1.40 (1.17–1.67)
Valvular disease 1.60 (1.48–1.72) 1.53 (1.35–1.74)
Valvular atrial fibrillation 1.64 (1.50–1.79) 0.96 (0.85–1.07)
Non-valvular atrial fibrillation 1.18 (1.13–1.24) 1.03 (0.98–1.08)
Cardioversion 0.90 (0.70–1.16) 0.86 (0.67–1.12)
Cardiomyopathy 1.02 (0.84–1.23) 0.94 (0.78–1.15)
Valve prosthesis 1.42 (1.27–1.57) 0.90 (0.78–1.04)
Mitral stenosis 2.12 (1.42–3.16) 1.33 (0.88–2.00)
Comorbidities/risk factorsa
Hypertensionb 1.73 (1.66–1.81) 1.22 (1.16–1.28)
Diabetes mellitus 1.68 (1.59–1.78) 1.16 (1.04–1.28)
Myocardial infarction 1.66 (1.57–1.75) 1.07 (0.99–1.17)
Ischemic heart disease 1.63 (1.55–1.71) 1.01 (0.93–1.09)
Peripheral vascular disease 1.93 (1.78–2.09) 1.28 (1.17–1.39)
Congestive heart failure 1.75 (1.66–1.84) 1.19 (1.12–1.26)
Renal failureb 3.13 (2.87–3.41) 1.82 (1.66–2.00)
Liver failureb 2.07 (1.73–2.46) 1.43 (1.19–1.72)
Ischemic stroke or TIAb 1.40 (1.33–1.48) 1.07 (1.00–1.13)
Chronic obstructive pulmonary disease/emphysema 1.79 (1.66–1.94) 1.18 (1.09–1.29)
Cancer (excl. non-melanoma skin cancer) 1.68 (1.57–1.79) 1.33 (1.24–1.42)
Alcohol dependency diagnosisb 2.04 (1.80–2.31) 1.79 (1.57–2.05)
Platelet or coagulation disorder 1.43 (1.18–1.74) 1.13 (0.92–1.37)
Prior bleedingb 2.63 (2.48–2.79) 1.85 (1.74–1.97)
Co-medicationa
Low-dose aspirinb 1.34 (1.28–1.39) 0.95 (0.91–1.00)
Other antiplatelet agentsb 1.60 (1.49–1.71) 1.17 (1.09–1.26)
NSAIDsb 1.01 (0.96–1.06) 1.06 (1.00–1.12)
PPIs 1.46 (1.40–1.53) 1.09 (1.04–1.15)
Antidepressants 1.43 (1.34–1.51) 1.23 (1.16–1.31)
Systemic corticosteroids 1.47 (1.39–1.56) 1.20 (1.13–1.27)
Alcohol dependency drugsb 1.81 (1.37–2.39) 1.49 (1.11–1.99)
Antidiabetics 1.47 (1.39–1.56) 1.06 (0.96–1.17)
a Yes vs no
b Included in the modified HAS-BLED score
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anticoagulation therapy in high-risk patients reported for both
sexes. At the same time, an overuse of anticoagulation was
also reported in individuals with a low risk of stroke [46].
Meta-analyses on sex differences in stroke in AF patients
found higher risk of stroke in women [6, 47], and in patients
with ischemic stroke and ICH, there were fewer women with
good post-stroke functioning compared to men [48], and a
possible higher net clinical benefit of VKA treatment in wom-
en was suggested in a study showing a slightly higher rate of
stroke in women [7]. Our results could partially reflect the fact
that the physicians avoid anticoagulation treatment in women
with a high bleeding risk to a higher extent than in high-risk
men, especially in the older age groups.
Strengths and limitations
The use of data from population-based healthcare registers
with full coverage implies that we avoided recall bias and that
there is no selection bias related to the study population. By
using the validated bleeding diagnoses by Friberg et al. [23],
we ensured the correct identification of the outcome.
With the introduction of the NOACs, prescription patterns
changed, and switches between the different antithrombotic
substances became common [49].We therefore chose a period
before the introduction of NOACs to avoid the complexity
with several different antithrombotic substances and indica-
tions to consider and a possible selection bias related to the
choice of therapy (channelling).
The PDR lacks information on indications, and therefore
diagnoses from the NPR corresponding to the indication for
warfarin treatment were used as a proxy. Receiving a certain
diagnosis depends on patient or physician attitudes and care-
seeking behaviour, which potentially could lead to sex differ-
ences in diagnoses recorded in the registers. Women have
more contact with the healthcare system throughout their
lifespan [50–52], which gives them an extra opportunity for
disease detection and perhaps more diagnoses/comorbidities.
We thus cannot exclude that differential misclassification of
diagnoses in women and men could have affected our results.
Furthermore, some NSAIDs are available over-the-counter
(OTC). Therefore, NSAID use is likely underestimated in
our analysis which is based on dispensed prescriptions.
Information on dosage and dates of treatment discontinua-
tion were not available. We performed an intention-to-treat
analysis, with the assumption that the warfarin treatment was
ongoing throughout the 12-month follow-up period. A gender
difference in adherence to warfarin treatment could have con-
tributed to the sex difference in severe bleeding. However, a
Swedish nationwide observational study showed no differ-
ence between women and men for persistence to warfarin
treatment in patients prescribed secondary preventive drugs
after stroke [53]. Similarly, differential adherence or persis-
tence could lead to biased effects of other risk factors.
Our results may be confounded by patient frailty. Age and
several of the chronic comorbidities we include in the analysis
are likely to be associated with frailty, but clinical assessments
of frailty were not available. It is noted that the association of
bleeding risk with age is only moderately attenuated after
adjustment, which could be ascribed to confounding by un-
measured frailty.
We did not have access to diagnoses from primary care,
and therefore, we do not have complete information on co-
morbidities. Hypertension was adjusted for in our analysis,
but no data on blood pressure control were available. In a
study with data from the Swedish Primary Care
Cardiovascular Database, fewer women than men reached tar-
get blood pressure [54], but among US adults, women had
generally higher hypertension control [55]. Sex differences
in hypertension control could potentially contribute to differ-
ences in the risk of severe bleeding.
Finally, it is a limitation that our study lacked data on INR
and time in therapeutic range (TTR). The adjustment for di-
agnoses representing the indication for treatment may in part
control for systematic differences in INR level and monitoring
intensity. For example, valvular disease was associated with a
higher bleeding risk. In a study investigating adverse out-
comes in women and men with AF taking warfarin in the
AMADEUS trial, TTR but not female sex was an independent
predictor for combined cardiovascular death and stroke/
systemic embolism and clinically relevant bleeding events
[11]. Studies based on data from the Swedish national quality
registry for AF and anticoagulation have shown that there was
no significant difference in TTR between women and men
[56, 57]. However, these studies did not assess the direction
of the INR deviation from the therapeutic range that could
result in either an increased risk of bleeding or an increased
risk of thromboembolic events. In a study on epidemiology of
subtherapeutic anticoagulation in the USA, women treated for
venous thromboembolism were particularly likely to experi-
ence low INR [58]. Thus, a lower treatment intensity in wom-
en could contribute to a lower bleeding risk.
Conclusion
In this population-based cohort study in patients on warfarin,
the majority of risk factors included in the HAS-BLED score
could be confirmed to be significantly associated with a higher
risk of bleeding. We also identified an association with several
other comorbidities, i.e. diabetes, peripheral vascular disease,
congestive heart failure, COPD and cancer. Women had a
lower overall incidence of severe bleeding even after adjusting
for age, comorbidity and co-medication. The apparent effect
of sex was, however, relatively small compared with the ef-
fects of other risk factors.
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Our findings could partially be explained by selection ef-
fects and confounding due to the limitations of our data, in-
cluding unmeasured confounders, notably treatment intensity
and patient frailty.
The individualized dosing may be a key factor, and there-
fore, exploring risk factors including sex differences in severe
bleeding in patients on NOACs with standardized dosing be-
comes highly relevant. Future studies should also investigate
factors not present in healthcare registers that may influence
treatment choice and intensity of treatment. For VKA, includ-
ing information on INR is highly relevant.
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